Opinion|Videos|October 14, 2026
Myeloma Experts Discuss Key Abstracts From the 2026 IMS Meeting
Fact checked by: Sabrina Serani
In this episode of The OncoloGIST, myeloma experts discuss the abstracts they most anticipated at IMS 2026, including EXCALIBER-RRMM and PERSEUS.
Advertisement
Episodes in this series
In this episode of The OncoloGIST, Drs Hans Lee, Gurbakhash Kaur, Saad Usmani, and Jessica Encinas Mayoral discuss the abstracts they most anticipated at the 2026 International Myeloma Society (IMS) Annual Meeting, held September 23-26 in Glasgow, Scotland. The panel highlights data from the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma and long-term follow-up from the phase 3 PERSEUS trial, and reflects on what these findings could mean for clinical practice.
Advertisement
Related to this article
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
2
Durability of PFS and OS Benefit vs. Historical Control
3
How Disease Burden Shapes First-Line RCC Treatment Selection
4
Rivoceranib Plus Camrelizumab Resubmitted to FDA in Frontline HCC
5